EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Osteoporosis, breast cancer - No. 690 Imprimer
Chlebowski et al (J Clin Oncol. 2010 Aug 1;28(22):3582-90. Epub 2010 Jun 21) evaluated the association between oral bisphosphonate use and invasive breast cancer was in postmenopausal women enrolled onto the WHI. Of the 154,768 participants, 2,816 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate). As calculated hip fracture risk score was significantly associated with both BMD (regression line = 0.79 to 0.0478 log predicted fracture; P < .001; r = 0.43) and breast cancer incidence (P = .03), this variable was incorporated into regression analyses to adjust for BMD difference between users and nonusers of bisphopshonate. After 7.8 mean years of follow-up (standard deviation, 1.7), invasive breast cancer incidence was lower in bisphosphonate users (hazard ratio [HR], 0.68; 95% CI, 0.52 to 0.88; P < .01) as was incidence of estrogen receptor (ER) -positive invasive cancers (HR, 0.70; 95% CI, 0.52 to 0.94, P = .02). A similar but not significant trend was seen for ER-negative invasive cancers. The incidence of ductal carcinoma in situ was higher in bisphosphonate users (HR, 1.58; 95% CI, 1.08 to 2.31; P = .02).
 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн